Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: LoLoLoLita who wrote (182)	4/27/1998 8:18:00 PM
From: Barron Von Hymen	Read Replies (1) \| Respond to of 641

No. What I mean to say, is that the anti-cancer effects should not be surprising based on the fact that the drug Evista targets the same molecular receptor as Tamoxifen does, so in theory should have the same biological effects with differences in potency and side effects, etc. Therefore I'm willing to bet that they will be able to explain scientifically (hence rationally) on a pharmacological basis, the empirical data that they have observed, even though they just happened upon that empirical data. In addition, the rationale behind their proof of activity will probably be widely accepted. Further, better planned studies of course are definitely warranted, in the interest of public health, and I'm making an educated guess that these studies will not surprise.